Iron chelation, angiogenesis and tumor therapy
- 14 May 2003
- journal article
- Published by Wiley in International Journal of Cancer
- Vol. 106 (3) , 458-459
- https://doi.org/10.1002/ijc.11223
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- The antimycotic ciclopirox olamine induces HIF‐1α stability, VEGF expression, and angiogenesisThe FASEB Journal, 2003
- Cellular adaptation to hypoxia: O2‐sensing protein hydroxylases, hypoxia‐inducible transcription factors, and O2‐regulated gene expressionThe FASEB Journal, 2002
- The antifungal drug ciclopirox inhibits deoxyhypusine and proline hydroxylation, endothelial cell growth and angiogenesis in vitroInternational Journal of Cancer, 2002
- Desferrioxamine enhances aids‐associated Kaposi's sarcoma tumor development in a xenograft modelInternational Journal of Cancer, 2002
- C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl HydroxylationCell, 2001
- Iron Chelators Inhibit the Growth and Induce the Apoptosis of Kaposi's Sarcoma Cells and of their Putative Endothelial PrecursorsJournal of Investigative Dermatology, 2000
- Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosisJournal of the American Academy of Dermatology, 2000
- Epolones induce erythropoietin expression via hypoxia-inducible factor-1α activationBlood, 2000
- The Relationship of Intracellular Iron Chelation to the Inhibition and Regeneration of Human Ribonucleotide ReductaseJournal of Biological Chemistry, 1996
- Cell cycle blockers mimosine, ciclopirox, and deferoxamine prevent the death of PC12 cells and postmitotic sympathetic neurons after removal of trophic supportJournal of Neuroscience, 1996